UPDATE: Credit Suisse Starts Vicarious Surgical inc. (RBOT) at Outperform

Credit Suisse analyst Matt Miksic initiates coverage on Vicarious Surgical inc. (NYSE: RBOT) with a Outperform rating and a price target of $16.00.

The analyst comments "Vicarious Surgical (RBOT) is an innovative and disruptive medical technology company targeting the large, expanding, and largely underpenetrated market for digital surgery. Vicarious addresses key challenges facing the adoption of robotic surgery technology, including ease of use, versatility, portability, and cost/benefit. Robotic surgery technology is used in less than 5% of total U.S. surgeries, due in part to these challenges. We are initiating coverage of RBOT with an Outperform rating and a $16 target price."

For an analyst ratings summary and ratings history on Vicarious Surgical inc. click here. For more ratings news on Vicarious Surgical inc. click here.

Shares of Vicarious Surgical inc. closed at $9.31 yesterday.

You May Also Be Interested In

• Deutsche Bank Starts Ardagh Metal Packaging S.A. (AMBP) at Hold
• BofA Securities Starts ProQR Therapeutics N.V. (PRQR) at Buy
• Marti Technologies (MRT) PT Raised to $6 at Benchmark on Stronger Growth, Improved Earnings Visibility